Correction to: Efficacy of Ronopterin (VAS203) in Patients with Moderate and Severe Traumatic Brain Injury (NOSTRA phase III trial): study protocol of a confirmatory, placebocontrolled, randomised, double blind, multi-centre study

Trials. 2020 Feb 12;21(1):172. doi: 10.1186/s13063-020-4107-8.

Authors

Affiliations

¹ vasopharm GmbH, Würzburg, Germany.
² vasopharm GmbH, Würzburg, Germany. schinzel@vasopharm.de.
³ Medizinische Universität Innsbruck, Innsbruck, Austria.
⁴ Wessex Neurological Centre University Hospital, Southampton, UK.
⁵ Hopital Universitaire Caremeau, Nimes, France.
⁶ Vall d'Hebron University Hospital, Barcelona, Spain.
⁷ Universitätsklinikum Heidelberg, Heidelberg, Germany.
⁸ Western General Hospital Lothian University, Edinburgh, UK.
⁹ Queen Elizabeth Hospital, Birmingham, UK.
¹⁰ Espases University Hospital, Palma de Mallorca, Spain.
¹¹ Hospital Universitario 12 de Octubre, Madrid, Spain.
¹² LKH - Universitätsklinikum Graz, Graz, Austria.
¹³ Medizinische Universität Wien, Wien, Austria.
¹⁴ Universitätsklinikum Schleswig-Holstein, Kiel, Germany.

Abstract

After publication of our article [1] the authors have notified us that one of the names has been incorrectly spelled.

Publication types

Published Erratum